The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients

European Archives of Psychiatry and Clinical Neuroscience

Volumn 261, Issue 3, 2011, Pages 173-177

  Paslakis, Georgios ^a   Gilles, Maria ^a   Lederbogen, Florian ^a   Schilling, Claudia ^a   Scharnholz, Barbara ^a   Deuschle, Michael ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Antidepressant; Cortisol; Depression; HPA axis; Metabolic syndrome; Reboxetine

Indexed keywords

DEXAMETHASONE; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REBOXETINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART RATE; HOSPITAL PATIENT; HUMAN; MAJOR DEPRESSION; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SALIVA ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WAIST HIP RATIO;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; DEPRESSION; FEMALE; HUMANS; INPATIENTS; MALE; METABOLIC DISEASES; MIDDLE AGED; MORPHOLINES; TIME FACTORS;

EID: 79958694164     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-010-0164-4     Document Type: Article

References (22)

1. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ (2001) The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24:1069-1078 (Pubitemid 33716379)
2. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-758
3. Engum A (2007) The role of depression and anxiety in onset of diabetes in a large population-based study. J Psychosom Res 62:31-38 (Pubitemid 44937341)
4. Everson-Rose SA, Meyer PM, Powell LH et al (2004) Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care 27:2856-2862 (Pubitemid 39565049)
5. Ford ES, Wayne HG, Mokdad AH (2004) Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 27:2444-2449 (Pubitemid 39281399)
6. Heiskanen TH, Niskanen LK, Hintikka JJ et al (2006) Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 67:1422-1427 (Pubitemid 44583390)
7. Knol MJ, Twisk JWR, Beekman ATF et al (2006) Depression as a risk factor for the onset of type 2 diabetes mellitus. A Metaanalysis Diabetol 49:837-845
8. Kopf D, Westphal S, Luley CW, Ritter S, Gilles M, Weber-Hamann B, Lederbogen F, Lehnert H, Henn FA, Heuser I, Deuschle M (2004) Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism and antidepressant treatment. J Clin Psychopharmacol 24(5):527-531 (Pubitemid 39274207)
9. Koponen H, Jokelainen J, Keinänen-Kiukaanniemi S, Kumpusalo E, Vanhala M (2008) Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J Clin Psychiatry 69:178-182 (Pubitemid 351469259)
10. Lederbogen F, Gernoth C, Hamann B, Kniest A, Heuser I, Deuschle M (2003) Circadian blood pressure regulation in hospitalized depressed patients and non-depressed comparison subjects. Blood Press Monit 8:71-76 (Pubitemid 36677276)
11. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223 (Pubitemid 41345943)
12. Lustman PJ, Freedland KE, Griffith LS, Clouse RE (2000) Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 23:618-623 (Pubitemid 30321540)
13. Okamura F, Tashiro A, Utumi A et al (2000) Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 49:1255-1260
14. Richter N, Juckel G, Assion HJ (2010) Metabolic syndrome: a follow-up study of acute depressive inpatients. Eur Arch Psychiatry Clin Neurosci 260:41-49
15. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van HT, Renn W, Gerich J (2000) Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23:295-301 (Pubitemid 30131733)
16. Teixeira PJ, Rocha FL (2007) The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 29:330-336 (Pubitemid 351358057)
17. Thakore JH, Richards PJ, Reznek RH, Martin A, Dinan TG (1997) Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol Psychiatry 41:1140-1142 (Pubitemid 27240009)
18. Timonen M, Rajala U, Jokelainen J, Keinänen-Kiukaanniemi S, Meyer-Rochow VB, Räsänen P (2006) Depressive symptoms and insulin resistance in young adult males: results from the Northern Finland 1966 birth cohort. Mol Psychiatry 11:929-933 (Pubitemid 44470215)
19. Vogelzangs N, Suthers K, Ferrucci L, Simonsick EM, Ble A, Schrager M, Bandinelli S, Lauretani F, Giannelli SV, Penninx BW (2007) Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology 32:151-159 (Pubitemid 46274017)
20. Weber-Hamann B, Hentschel F, Kniest A, Deuschle M, Colla M, Lederbogen F, Heuser I (2002) Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med 64(2):274-277 (Pubitemid 34260465)
21. Weber-Hamann B, Gilles M, Lederbogen F et al (2006) Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 67:1856-1861 (Pubitemid 46048182)
22. Weber-Hamann B, Gilles M, Schilling C, Onken V, Frankhauser P, Kopf D, Lederbogen F, Deuschle M (2008) Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine. J Clin Psychopharmacol 28:581-584